Results of statistical analysis among splenic histologic subgroups in 213 splenectomized patients with myelofibrosis with myeloid metaplasia
| Parameter . | Pathology category (n = 213) . | Diffuse vs nodular (n = 196) . | Splenic infarct (n = 26) . |
|---|---|---|---|
| General parameters | |||
| Number of patients | D = 121 (56.8%) | D = 121 (61.7%) | 26 (12.2%) |
| N = 75 (35.2%) | N = 75 (38.3%) | ||
| PPIG = 17 (8.0%) | |||
| Survival | |||
| From diagnosis | .04 | .17 | .01 |
| From splenectomy | .29 | .82 | .02 |
| Cause of death | .39 | .14 | .85 |
| Dupriez score* | |||
| At diagnosis | .09 | .02† | < .01 |
| At splenectomy | .04 | .01 | .20 |
| Time to splenectomy (from diagnosis) | .82 | .16 | .18 |
| Parameters at the time of splenectomy | |||
| Age | .99 | .53 | .38 |
| Laboratory values | |||
| Hemoglobin < 9 g/dL | .20 | .10 | .09 |
| RBC transfusion dependent (yes/no) | < .01 | .02 | .09 |
| Leukocyte count | .27 | .49 | .16 |
| Platelet count < 50 × 109/L | < .01 | < .01† | < .01† |
| Circulating blasts | .44 | .44 | .04 |
| Spleen mass | .70 | .10 | .63 |
| Splenic infarct (yes/no) | .90 | .56 | — |
| Perioperative complications | |||
| Bleeding | .87 | 1.0 | .02 |
| Thrombosis | 1.0 | 1.0 | .23 |
| Long-term complications | |||
| Leukemia | .65 | .75 | .08 |
| Thrombocytosis | .27 | 1.0 | .62 |
| Hepatomegaly | .70 | .43 | .77 |
| Parameter . | Pathology category (n = 213) . | Diffuse vs nodular (n = 196) . | Splenic infarct (n = 26) . |
|---|---|---|---|
| General parameters | |||
| Number of patients | D = 121 (56.8%) | D = 121 (61.7%) | 26 (12.2%) |
| N = 75 (35.2%) | N = 75 (38.3%) | ||
| PPIG = 17 (8.0%) | |||
| Survival | |||
| From diagnosis | .04 | .17 | .01 |
| From splenectomy | .29 | .82 | .02 |
| Cause of death | .39 | .14 | .85 |
| Dupriez score* | |||
| At diagnosis | .09 | .02† | < .01 |
| At splenectomy | .04 | .01 | .20 |
| Time to splenectomy (from diagnosis) | .82 | .16 | .18 |
| Parameters at the time of splenectomy | |||
| Age | .99 | .53 | .38 |
| Laboratory values | |||
| Hemoglobin < 9 g/dL | .20 | .10 | .09 |
| RBC transfusion dependent (yes/no) | < .01 | .02 | .09 |
| Leukocyte count | .27 | .49 | .16 |
| Platelet count < 50 × 109/L | < .01 | < .01† | < .01† |
| Circulating blasts | .44 | .44 | .04 |
| Spleen mass | .70 | .10 | .63 |
| Splenic infarct (yes/no) | .90 | .56 | — |
| Perioperative complications | |||
| Bleeding | .87 | 1.0 | .02 |
| Thrombosis | 1.0 | 1.0 | .23 |
| Long-term complications | |||
| Leukemia | .65 | .75 | .08 |
| Thrombocytosis | .27 | 1.0 | .62 |
| Hepatomegaly | .70 | .43 | .77 |
All results (except those for distribution) reflect aP value from univariate analysis. Column 1, D vs N vs PPIG; column 2, D vs N only.
D indicates diffuse extramedullary hematopoiesis pattern; N, nodular extramedullary hematopoiesis pattern; PPIG, predominant presence of immature granulocytes in splenic extramedullary hematopoiesis; RBC, red blood cell.
Dupriez prognostic score for myelofibrosis with myeloid metaplasia.11
Significant in multivariate analysis using logistic regression.